Cargando…
Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells
Chimeric antigen receptor modified T cells (CAR-T) therapy is an emerging immunotherapy against malignancies. However, only limited success was obtained in solid tumors. Polyinosinic-polycytidylic acid (poly I:C), ligand of TLR3, mediates innate immune and adaptive immune and shows broad antitumor e...
Autores principales: | Di, Shengmeng, Zhou, Min, Pan, Zeyan, Sun, Ruixin, Chen, Muhua, Jiang, Hua, Shi, Bizhi, Luo, Hong, Li, Zonghai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481273/ https://www.ncbi.nlm.nih.gov/pubmed/31058074 http://dx.doi.org/10.3389/fonc.2019.00241 |
Ejemplares similares
-
Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells
por: Luo, Hong, et al.
Publicado: (2019) -
FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer
por: Liu, Yifan, et al.
Publicado: (2023) -
Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells
por: Jiang, Hua, et al.
Publicado: (2017) -
An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment
por: Wang, Yi, et al.
Publicado: (2019) -
Combined adjuvants of poly(I:C) plus LAG‐3‐Ig improve antitumor effects of tumor‐specific T cells, preventing their exhaustion
por: Kano, Yosuke, et al.
Publicado: (2016)